伊布替尼胶囊Ibrutinib 140mg

For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. For adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). For adult patients with CLL/SLL with 17p deletion. For adult patients with Waldenström's macroglobulinemia (WM). For adult and pediatric patients aged 1 year and older with chronic graft-versus-host disease (cGVHD) who have failed one or more lines of systemic immune therapy.

MCL 560 mg orally once daily CLL/SLL, WM 420 mg orally once daily cGVHD (patients aged 12 years and older) 420 mg orally once daily cGVHD (patients aged 1 to under 12 years) 240 mg/m² orally once daily (maximum dose: 420 mg)

This product may increase the risk of bleeding in patients receiving antiplatelet or anticoagulant therapy; monitor patients for signs of bleeding. For patients at increased risk of opportunistic infections, consider prophylaxis in accordance with standard treatment guidelines. Interstitial Lung Disease (ILD): If ILD symptoms occur, suspend treatment with this product and administer appropriate ILD therapy. If symptoms persist, evaluate the benefit-risk profile of continued treatment and make appropriate dose adjustments. Exercise caution when administering this product to pregnant women, children, and elderly patients. Concomitant use with potent CYP3A inhibitors requiring long-term administration is not recommended. Administration of this product is not recommended for patients with moderate or severe hepatic impairment (Child-Pugh Class B and C).

Neutropenia, thrombocytopenia, anemia, diarrhea, musculoskeletal pain, nausea, rash, bruising, fatigue, pyrexia, bleeding, etc.

120 capsules per bottle.

Store tightly closed below 30℃. Keep out of the reach of children.